Monitoring and Treatment Selection for a Community Patient

One panelist addresses neuropathy in a patient who has received bortezomib, describing a symptom-driven approach. Asked what else to monitor, the other panelist describes adverse effects to monitor based on the drug class as well. The moderator then presents the first clinical scenario, a 68-year-old patient after 2 prior lines who lives 45 minutes away and declined CAR T-cell therapy. One panelist calls this a typical community patient who has not received a CD38 antibody, and weighs a BCMA antibody-drug conjugate regimen, a newly approved CELMoD-based regimen, and an oral option, favoring an every-3-week option for this clinical scenario.